Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
- Resource Type
- Source
- Blood. 140:7272-7274
- Subject
Immunology Cell Biology Hematology Biochemistry - Language
- ISSN
- 1528-0020
0006-4971